Cytokinetics: Specialty Franchise With Aficamten And Ulacamten

Core Insights - Cytokinetics, Incorporated is a cardiology company focusing on a late-stage pipeline that includes Aficamten, a therapy for obstructive hypertrophic cardiomyopathy (oHCM) [1] - The PDUFA date for Aficamten has been delayed to December 2025, indicating a potential impact on the company's timeline for product launch and revenue generation [1]